InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Asset Writedowns and Impairment of $208737.0 for Q4 2025, little changed quarter-over-quarter from $208737.0 in Q2 2025.
InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends
InMed Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $208737.0 for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $208737.0; the TTM figure through Dec 2025 stood at $208737.0 (changed N/A YoY), while the FY2025 annual figure was $208737.0, down 31.74% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $208737.0, roughly flat from $208737.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $576772.0 in Q3 2022, with the low at -$551687.0 in Q4 2022.
- The 4-year median for Asset Writedowns and Impairment is $131702.0 (2023), against an average of $96257.6.
- The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment plunged 83.89% in 2023, then soared 392.21% in 2025.
- InMed Pharmaceuticals' Asset Writedowns and Impairment stood at -$551687.0 in 2022, then jumped by 130.9% to $170474.0 in 2023, then slumped by 75.12% to $42408.0 in 2024, then soared by 392.21% to $208737.0 in 2025.
- Business Quant data shows INM's Asset Writedowns and Impairment at $208737.0 in Q4 2025, $208737.0 in Q2 2025, and $42408.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 208,737.00 |
| Dec 31, 2025 | 208,737.00 |
| Jun 30, 2025 | 208,737.00 |
| Jun 30, 2025 | 208,737.00 |
| Jun 30, 2024 | 42,408.00 |
| Jun 30, 2024 | 42,408.00 |
| Dec 31, 2023 | 170,474.00 |
| Dec 31, 2023 | 170,474.00 |
| Sep 30, 2023 | 92,930.00 |
| Sep 30, 2023 | 92,930.00 |
| Jun 30, 2023 | 21,690.00 |
| Jun 30, 2023 | 21,690.00 |
| Dec 31, 2022 | -551,687.00 |
| Dec 31, 2022 | -551,687.00 |
| Sep 30, 2022 | 576,772.00 |
| Sep 30, 2022 | 576,772.00 |